<DOC>
	<DOCNO>NCT00488839</DOCNO>
	<brief_summary>The purpose study determine effect , good bad , IPX056 subject spasticity . This study also determine relationship amount IPX056 blood effect spasticity . Lastly , study determine long IPX056 affect spasticity .</brief_summary>
	<brief_title>IPX056 Subjects With Established Spasticity Resulting From Multiple Sclerosis</brief_title>
	<detailed_description>The primary objective study demonstrate IPX056 reduce spasticity , measure Ashworth score , subject multiple sclerosis ( MS ) . This study also ( 1 ) ass correlation pharmacokinetic ( PK ) pharmacodynamic ( PD ) endpoint ( Ashworth score ) , ( 2 ) quantify duration pharmacodynamic effect IPX056 well market baclofen tablet subject Multiple Sclerosis ( MS ) single dose . Additionally , efficacy parameter , include Multiple Sclerosis Impact Scale ( MSIS ) -29 , spasm frequency nighttime awaken score , spasticity control , morning stiffness , Global Assessment Efficacy Tolerability , assess open-label extension period . The safety IPX056 monitor throughout study . This study consist 2 part : Part I ( Screening Visit &amp; Visit 1 ) study single-dose , double-blind , randomize , placebo- active comparator-controlled , parallel group design contain single 12 hour PK/PD evaluation period . Part II optional , approximately 9-week open-label extension study start Visit 1 , immediately Visit 1 PK/PD procedure complete .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>Male female least 18 year old . If female childbearing potential , continue practice willing continue throughout study appropriate contraceptive ( defined oral , inject , implanted contraceptive , barrier contraception ) . The subject must agree take every precaution ensure pregnancy occur study . Female subject childbearing potential must negative urine pregnancy test immediately prior study entry . Able understand willing voluntarily sign informed consent form ( ICF ) Authorization Use Disclose Protected Health Information form ( require Health Insurance Portability Accountability Act { HIPAA } legislation , appropriate region ) prior performance studyspecific procedure . Has negative urine drug screen screen visit . Has Definite multiple sclerosis Poser McDonald Criteria . Expanded Disability Status Scale ( EDSS ) rating 3.08.0 Has normal ECG blood pressure &lt; 160/95 mmHg ( systolic ) /diastolic ) screening , measure sit position approximately 5 minute quiet rest . If subject history presence clinically significant peptic ulcer , liver disease , diabetes mellitus , hypertension heart disease , subject must stable treatment regimen minimum 3 month prior Screening Visit Wiling wash current medication antispasticity activity , include limited baclofen , benzodiazepine , clonazepam , clonidine , dantrolene , diazepam , gabapentin , tizanidine . Ashworth score 2 least one three low extremity muscle group ( hip adductor , knee flexor , knee extensor ) affect limb total minimum score 6 four muscle group ( three plus plantar flexor ) limb ( maximum total score 32 ) screen visit predose PK/PD Visit 1 . Able willing comply protocol , include availability schedule clinic visit If female , subject : 1. pregnant ; plan become pregnant ; 2. breastfeeding ; 3. woman childbearing potential ( define post menarche biologically capable become pregnant [ i.e. , surgically sterile ] ) engage active heterosexual relation use barrier hormonal form birth control ( i.e . oral , injected , implanted contraceptive ) . History allergic severe intolerance baclofen . Did respond previous baclofen treatment formulation . Treated intrathecal baclofen within previous 6 month prior Screening Visit . Has experience exacerbation MS within 6 month prior Screening Visit . Symptomatic urinary tract infection ( UTI ) within 4 week prior Screening Visit two ( 2 ) UTI incident within last 6 month . Serum creatinine level ≥ 2 x ULN ( upper limit normal reference range ) Screening Visit require dialysis . Liver enzyme value ≥ 2 x ULN ( upper limit normal reference range ) Screening Visit . Uncontrolled peptic ulcer , liver disease , diabetes mellitus , bladder sphincter hypertonia , hypertension heart disease . History seizure epilepsy , currently take anticonvulsant treatment control seizure . Concomitant neurologic condition cause spasticity ( e.g . stroke , cerebral palsy , traumatic brain injury ) rigidity ( e.g . Parkinson 's disease ) . Any medical condition , include psychiatric disease , would interfere interpretation study result , conduct study , safety subject . Currently take antipsychotic , CNS depressants CNS depression produce medication ( include alcohol , sedate antihistamine , barbiturate , narcotic , phenothiazine ) , monoamine oxidase inhibitor ( MAOI , include furazolidone , procarbazine , selegiline , tranylcypromine ) , tricyclic . Unable unwilling wash current antispasticity medication , include limited baclofen , benzodiazepine , clonazepam , clonidine , dantrolene , diazepam , gabapentin , and/or tizanidine Day 1 , Visit 1 , procedure . However , medication allow open label study . Unable unwilling participate 12hour PK/PD procedure Visit 1 . Treated Botulinum Toxin Type A B within previous 6 month , Phenol therapeutic alcohol nerve block within 12 month prior Screening Visit . History alcohol abuse use recreational drug within 12 month prior Screening Visit . Has receive investigational drug device within 30 day prior Screening Visit . Has clinically significant limitation passive range motion around joint assess study . Has major surgery within 3 month prior Screening visit may affect spasticity assessment abdominal surgery , back surgery , low leg knee surgery .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Spasticity</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>